A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

NCT00658671 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
67
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CASI pharmaceuticals, Inc.